Report generated from BNF provided by FormularyComplete ( Accessed Formulary Status. TA Number. Section.

Size: px
Start display at page:

Download "Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section."

Transcription

1 Report generated from BNF provided by FormularyComplete ( Accessed Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE Allergic emergencies->anaphylaxis Adrenoceptor agonists 3.1 Bronchodilators AeroChamber Plus Alimemazine ALIMEMAZINE TARTRATE 3.1 Bronchodilators->3.1.5 Peak flow meters, inhaler devices and nebulisers->drug delivery devices Antihistamines->Sedating antihistamines->alimemazine TARTRATE Antihistamines->Sedating antihistamines Allergen immunotherapy 3.4 Antihistamines, hyposensitisation, and allergic emergencies Allergic emergencies 3.4 Antihistamines, hyposensitisation, and allergic emergencies AMINOPHYLLINE 3.1 Bronchodilators->3.1.3 Theophylline Aminophylline 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE Anaphylaxis Allergic emergencies Antihistamines 3.4 Antihistamines, hyposensitisation, and allergic emergencies Antihistamines, hyposensitisation, and allergic emergencies Antimuscarinic bronchodilators Aromatic inhalations 3.1 Bronchodilators Asmabec Clickhaler 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Atarax Antihistamines->Sedating antihistamines->hydroxyzine

2 Atrovent bronchodilators->ipratropium BROMIDE Beclometasone 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE BECLOMETASONE DIPROPIONATE Benzoin Tincture, Compound, BP 3.2 Corticosteroids 3.8 Aromatic inhalations Bronchitol 3.7 Mucolytics->Mannitol->MANNITOL Bronchodilators BUDESONIDE 3.2 Corticosteroids Budesonide 3.2 Corticosteroids->BUDESONIDE CARBOCISTEINE 3.7 Mucolytics Carbocisteine 3.7 Mucolytics->CARBOCISTEINE Cetirizine CETIRIZINE Chlorphenamine CHLORPHENAMINE MALEATE Codeine Linctus, BP Antihistamines->Non-sedating antihistamines->cetirizine Antihistamines->Non-sedating antihistamines Antihistamines->Sedating antihistamines->chlorphenamine MALEATE Antihistamines->Sedating antihistamines 3.9 Cough ->3.9.1 Cough suppressants->codeine PHOSPHATE CODEINE PHOSPHATE 3.9 Cough ->3.9.1 Cough suppressants Compound bronchodilator Compound 3.1 Bronchodilators ->INDACATEROL Compound 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Compound tiotropium bronchodilators->tiotropium

3 Compound umeclidinium Corticosteroids Cough bronchodilators->umeclidinium Cough suppressants 3.9 Cough Cromoglicate and related therapy and phosphodiesterase type-4 inhibitors Curosurf 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants->poractant ALFA Approved for use on Neonatal Intensive Care Unit (D&T Minute 10/07/06)and will be reviewed in 12 months time. Stocks of Beractant (Survanta) to be run down. Daxas and phosphodiesterase type-4 inhibitors->3.3.3 Phosphodiesterase type-4 inhibitors->roflumilast Demulcent and expectorant cough 3.9 Cough DESLORATADINE Antihistamines->Non-sedating antihistamines Drug delivery devices 3.1 Bronchodilators->3.1.5 Peak flow meters, inhaler devices and nebulisers Duaklir Genuair bronchodilators->aclidinium BROMIDE->Compound DuoResp Spiromax 3.2 Corticosteroids->BUDESONIDE->Compound Eklira Genuair FEXOFENADINE Fexofenadine Hydrochloride bronchodilators->aclidinium BROMIDE Antihistamines->Non-sedating antihistamines Antihistamines->Non-sedating antihistamines->fexofenadine Flixotide 3.2 Corticosteroids->FLUTICASONE FLUTICASONE 3.2 Corticosteroids Formoterol ->FORMOTEROL FUMARATE

4 FORMOTEROL FUMARATE Fostair 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE->Compound First line LABA/ICS choice for COPD. Currently the only licensed MDI for COPD. Lower licensd ICS dose and cost than other LABA/ICS MDIs used "off-label". Commissioning and funding the responsibility of CCGs. HYDROXYZINE Antihistamines->Sedating antihistamines Incruse Ellipta bronchodilators->umeclidinium INDACATEROL Inhalation ->SALBUTAMOL Intal CFC-Free Inhaler and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy->sodium CROMOGLICATE Intramuscular adrenaline (epinephrine) Allergic emergencies->anaphylaxis Intramuscular injection for self-administration Allergic emergencies->anaphylaxis->adrenaline/epinephrine IPRATROPIUM BROMIDE bronchodilators Ipratropium Bromide Ipratropium Steri-Neb Jext Leukotriene receptor antagonists LORATADINE bronchodilators->ipratropium BROMIDE bronchodilators->ipratropium BROMIDE Allergic emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular injection for self-administration and phosphodiesterase type-4 inhibitors Antihistamines->Non-sedating antihistamines

5 Loratadine Antihistamines->Non-sedating antihistamines->loratadine MANNITOL 3.7 Mucolytics->Mannitol TA266 METHADONE 3.9 Cough ->3.9.1 Cough suppressants->palliative care Modified release 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE Modified release 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE Mucolytics Neoclarityn Antihistamines->Non-sedating antihistamines->desloratadine NINTEDANIB 3.11 Antifibrotics Non-sedating antihistamines Antihistamines OLODATEROL Omalizumab Allergen immunotherapy This drug is not used by the Trust as we do not provide services requiring its use. OMALIZUMAB Allergen immunotherapy->omalizumab TA339 This drug is not used by the Trust as we do not provide services requiring its use. OMALIZUMAB Allergen immunotherapy->omalizumab TA278 This drug is not used by the Trust as we do not provide services requiring its use. Onbrez Breezhaler ->INDACATEROL Oral and parenteral ->TERBUTALINE SULFATE Oxis ->FORMOTEROL FUMARATE Oxygen Parenteral ->SALBUTAMOL Peak flow meters 3.1 Bronchodilators->3.1.5 Peak flow meters, inhaler devices and nebulisers

6 Peak flow meters, inhaler devices and nebulisers 3.1 Bronchodilators Pharmalgen Allergen immunotherapy->bee AND WASP ALLERGEN EXTRACTS PAH Trust does not comission the service requiring use of this drug. Phenergan Antihistamines->Sedating antihistamines->promethazine PHOLCODINE 3.9 Cough ->3.9.1 Cough suppressants Pholcodine Linctus, BP 3.9 Cough ->3.9.1 Cough suppressants->pholcodine Phyllocontin Continus 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE->Modified release Piriton Antihistamines->Sedating antihistamines->chlorphenamine MALEATE PORACTANT ALFA 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants Approved for use on Neonatal Intensive Care Unit (D&T Minute 10/07/06)and will be reviewed in 12 months time. Stocks of Beractant (Survanta) to be run down. PROMETHAZINE Antihistamines->Sedating antihistamines PSEUDOEPHEDRINE 3.10 Systemic nasal decongestants Pulmicort 3.2 Corticosteroids->BUDESONIDE Pulmonary surfactants 3.5 Respiratory stimulants and pulmonary surfactants Qvar 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Relvar Ellipta 3.2 Corticosteroids->FLUTICASONE->Compound Respiratory stimulants 3.5 Respiratory stimulants and pulmonary surfactants Respiratory stimulants and pulmonary surfactants ROFLUMILAST and phosphodiesterase type-4 inhibitors->3.3.3 Phosphodiesterase type-4 inhibitors TA244 SALBUTAMOL

7 Salbutamol Sedating antihistamines Seebri Breezhaler ->SALBUTAMOL->Inhalation Antihistamines bronchodilators->glycopyrronium Selective 3.1 Bronchodilators->3.1.1 Adrenoceptor agonists Seretide 3.2 Corticosteroids->FLUTICASONE->Compound Simple Linctus, BP Simple Linctus, Paediatric, BP Slo-Phyllin SODIUM CROMOGLICATE 3.9 Cough ->3.9.2 Demulcent and expectorant cough 3.9 Cough ->3.9.2 Demulcent and expectorant cough 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE->Modified release and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy Spiolto Respimat 3.1 Bronchodilators->3.1.4 Compound bronchodilator Spiriva Striverdi Respimat Sudafed Systemic nasal decongestants Telfast TERBUTALINE SULFATE bronchodilators->tiotropium ->OLODATEROL 3.10 Systemic nasal decongestants->pseudoephedrine Antihistamines->Non-sedating antihistamines->fexofenadine Theophylline 3.1 Bronchodilators THEOPHYLLINE 3.1 Bronchodilators->3.1.3 Theophylline

8 TIOTROPIUM bronchodilators Ultibro Breezhaler 3.1 Bronchodilators->3.1.4 Compound bronchodilator UMECLIDINIUM bronchodilators Uniphyllin Continus 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE->Modified release Ventolin ->SALBUTAMOL->Parenteral Ventolin ->SALBUTAMOL->Inhalation Xolair Allergen immunotherapy->omalizumab->omalizumab This drug is not used by the Trust as we do not provide services requiring its use. Alvesco Restricted 3.2 Corticosteroids->CICLESONIDE Ciclesonide under review with Dr. Newberry giving patients the option of either nebulised steroids or high dose Ciclesonide (up to 4 times the licensed maximum dose). The committee to review this item again in 6 months time together with any new evidence for its use (i.e. Comparison with nebulised steroids)(d&t Minute 21/05/07) Bricanyl Restricted ->TERBUTALINE SULFATE->Oral and parenteral Injection available for use on Labour Ward for treating hyperstimulation due to Prostin induction. CICLESONIDE Restricted 3.2 Corticosteroids Ciclesonide under review with Dr. Newberry giving patients the option of either nebulised steroids or high dose Ciclesonide (up to 4 times the licensed maximum dose). The committee to review this item again in 6 months time together with any new evidence for its use (i.e. Comparison with nebulised steroids).(d&t Minute 21/05/07) Combivent Restricted 3.1 Bronchodilators->3.1.4 Compound bronchodilator Consultant psychiatrists can initiate treatment and jun Flutiform Restricted 3.2 Corticosteroids->FLUTICASONE->Compound Recommended for restricted prescribing in primary and secondary care.. Recommended as a fourth line treatment option when a high strenght LABA/ICS is indicated and patients are unable to use fluticasone/salmeterol (Seretide 500 Accuhaler DPI) device. SALMETEROL Restricted For patients who come into hospital on this treatment only. Serevent Restricted ->SALMETEROL For patients who come into hospital on this treatment only. Singulair Restricted and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists->montelukast for use by consultant chest physicians and consultant paediatricans only

Report generated from BNF with QVH Formulary provided by FormularyComplete ( Accessed Formulary Status.

Report generated from BNF with QVH Formulary provided by FormularyComplete (  Accessed Formulary Status. Report generated from BNF with QVH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed 09 10 2015 Title Formulary Status Section TA Number TA Link Annotation A2A Spacer Able Spacer Accolate

More information

3. Respiratory System

3. Respiratory System 1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)

More information

BNF CHAPTER 3: RESPIRATORY

BNF CHAPTER 3: RESPIRATORY 3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe

More information

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device 3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose

More information

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Respiratory Inhalers. Identification Guide Version 3

Respiratory Inhalers. Identification Guide Version 3 Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical

More information

Chapter 3: Respiratory System (7 th Edition)

Chapter 3: Respiratory System (7 th Edition) Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment

More information

RESPIRATORY PRESCRIBING SCHEMES GUIDE 2017/18

RESPIRATORY PRESCRIBING SCHEMES GUIDE 2017/18 impact500 www.ccgprescriber.org RESPIRATORY PRESCRIBING SCHEMES GUIDE 2017/18 TOTAL AVAILABLE NHS SAVINGS IN THIS EDITION 133 MILLION EDITION TWO Analysis was undertaken using May 2017 tariff and February

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information

Co. Durham & Darlington Respiratory Network COPD Treatment Guide

Co. Durham & Darlington Respiratory Network COPD Treatment Guide Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination

More information

These lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.

These lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece. Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.

More information

Dose. Route. Units. Given. Dose. Route. Units. Given

Dose. Route. Units. Given. Dose. Route. Units. Given Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening

More information

GMMMG COPD Formulary Inhaler Options October 2017

GMMMG COPD Formulary Inhaler Options October 2017 BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram

More information

CHARM Guidelines for the diagnosis and

CHARM Guidelines for the diagnosis and \ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,

More information

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled

More information

COPD Prescribing Guidelines

COPD Prescribing Guidelines Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning

More information

Please also see section on Drugs used in substance dependence for patients with established chemical dependence

Please also see section on Drugs used in substance dependence for patients with established chemical dependence Respiratory System Algorithm for the selection of the most appropriate inhaler device for patients with chronic stable asthma Information on Inhaler devices Devices β 2 agonist bronchodilators Antimuscarinic

More information

If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team

If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:

More information

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers

More information

CHARM ASTHMA TREATMENT GUIDELINE

CHARM ASTHMA TREATMENT GUIDELINE NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof

More information

THE COPD PRESCRIBING TOOL

THE COPD PRESCRIBING TOOL THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their

More information

3 RESPIRATORY SYSTEM

3 RESPIRATORY SYSTEM 3 RESPIRATORY SYSTEM 3.01 ANTIASTHMATICS 3.01a BETA 2 AGONIST ASTHMA, CHRONIC BRONCHITIS & EMPHYSEMA Salbutamol Inhaler 100ug/dose [Albuterol] (Ventolin) Salbutamol Sulphate Respirator Solution 0.5% (5mg/ml),

More information

Address Comorbidities

Address Comorbidities Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure

More information

THEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE

THEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management

More information

3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine

3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered

More information

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Respiratory Subcommittee minutes for web publishing

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Respiratory Subcommittee minutes for web publishing Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Respiratory Subcommittee minutes for web publishing Respiratory System and Allergies therapeutic group PTAC and Subcommittee

More information

RESPIRATORY INHALERS

RESPIRATORY INHALERS RESPIRATORY INHALERS The correct administration of inhaled therapy is essential for successful, cost-effective and safe therapy. Everyone, including the patient needs to understand the importance of ensuring

More information

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version

More information

3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine

3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered

More information

Respiratory Health. Asthma and COPD

Respiratory Health. Asthma and COPD Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory

More information

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

He is still Short of Breath Is there any new puffer? Saidul Ansary

He is still Short of Breath Is there any new puffer? Saidul Ansary He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,

More information

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial

More information

Summary of Lothian Joint Formulary Amendments

Summary of Lothian Joint Formulary Amendments Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The

More information

12:00 Autonomic Drugs 12:00. Autonomic Drugs

12:00 Autonomic Drugs 12:00. Autonomic Drugs Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON

More information

Position within the Organisation

Position within the Organisation ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September

More information

Respiratory system. Contents: 1. Asthma acute exacerbations

Respiratory system. Contents: 1. Asthma acute exacerbations Respiratory system Medicines Formulary Contents: 1. Asthma acute exacerbations 1 2. Asthma chronic 4 3. Chronic obstructive pulmonary disease acute exacerbations 6 4. Chronic obstructive pulmonary disease

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability

More information

Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline

Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline For use across all Norfolk & Waveney CCGs Based on GOLD 2017 1, NICE CG101 COPD 2. Norfolk & Waveney Group In the UK in 2012, 29,776

More information

Stepping down asthma treatment guidelines

Stepping down asthma treatment guidelines Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Lungs SLO Practice (online) Page 1 of 5

Lungs SLO Practice (online) Page 1 of 5 Lungs SLO Practice (online) Page 1 of 5 1. A 15 year- old teen has asthma. A nebulizer treatment has been ordered. The type of medication most likely to be used in this treatment for asthma management

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:

More information

Prescribing guidelines: Management of COPD in Primary Care

Prescribing guidelines: Management of COPD in Primary Care Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR

More information

Chronic Obstructive Pulmonary Disease (COPD) Management

Chronic Obstructive Pulmonary Disease (COPD) Management DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally

More information

COPD Inhaled Therapy Prescribing Guidance

COPD Inhaled Therapy Prescribing Guidance COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR

More information

COPD Inhaled Therapy Prescribing Guidance

COPD Inhaled Therapy Prescribing Guidance COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR

More information

COPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD

COPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

Bronchial Provocation Testing Using Mannitol

Bronchial Provocation Testing Using Mannitol Patient Information Leaflet Bronchial Provocation Testing Using Mannitol Information for patients, relatives and carers For more information, please contact: Cardio-Respiratory Department The York Hospital,

More information

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients

More information

Inhalers containing CFCs. CFC-free inhalers

Inhalers containing CFCs. CFC-free inhalers Propellants used in medical metered dose inhalers and aerosol-based breath activated devices in New Zealand August to October 2002 (most recent period for which data is available) (February 2003) Inhalers

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate

More information

Spirometry is a test that measures the size of your lungs and it also measures airflow in your lungs.

Spirometry is a test that measures the size of your lungs and it also measures airflow in your lungs. PATIENT INFORMATION This leaflet gives you general information about the lung function (breathing) tests. However, it does not replace the need for personal advice from the health care professional. Please

More information

Common Drug Review Pharmacoeconomic Review Report

Common Drug Review Pharmacoeconomic Review Report Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance

More information

Why should I read this booklet?

Why should I read this booklet? COPD The basics Why should I read this booklet? This booklet contains information for people who have recently been told by their doctor that they have a condition called Chronic Obstructive Pulmonary

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Why Asthma Still Kills The National Review of Asthma Deaths (NRAD)

Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net

More information

Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.

Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more. Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group

NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

Evidence Review for Prescribing Clinical Network

Evidence Review for Prescribing Clinical Network Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:

More information

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Better Living with Obstructive Pulmonary Disease A Patient Guide

Better Living with Obstructive Pulmonary Disease A Patient Guide Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

31 - Respiratory System

31 - Respiratory System 31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal

More information

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis

More information

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly

More information

Medicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids

Medicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning

More information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) NHS Eastern Cheshire Clinical Commissioning Group NHS South Cheshire Clinical Commissioning Group NHS Vale Royal Clinical Commissioning Group Mid Cheshire Hospitals NHS Foundation Trust East Cheshire NHS

More information

Respiratory Inhaler Check-up Service

Respiratory Inhaler Check-up Service Respiratory Inhaler Check-up Service Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 8 th May 2018 What is the Challenge? The Burden of Disease in

More information

What is the Challenge?

What is the Challenge? Respiratory Inhaler Check-up Service What is the Challenge? Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 25 th September 2018 The Burden of Disease

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Asthma Treatment Guideline for Adults (aged 17 and over)

Asthma Treatment Guideline for Adults (aged 17 and over) Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version

More information

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for

More information

Diagnosis and management of Asthma in Adults. (Version 1.1)

Diagnosis and management of Asthma in Adults. (Version 1.1) Pan-Birmingham Respiratory Clinical Network Diagnosis and management of Asthma in Adults (Version 1.1) Revision History Guideline Author: Guideline Sponsor: Date of Approval: 23/03/2017 Approved by: Date

More information

Algorithm for the use of inhaled therapies in COPD

Algorithm for the use of inhaled therapies in COPD Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information